Coronary Artery Disease Progression
17
6
8
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.9%
1 terminated out of 17 trials
75.0%
-11.5% vs benchmark
18%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (17)
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population
Disease Characteristics of R-CAD
Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
Disease Characteristics of IR-CAD: a Case-control Study
Proteomics and Genomics Combined With CT to Predict CVD
Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
Registry of Secondary Revascularization
Natural History of Coronary Atherosclerosis
Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease
Critical Treatment of Coronary Artery Disease
Sirtuin-1 and Advanced Glycation End-products in Postmenopausal Women With Coronary Disease
Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial